Figure 2.
Response to atezolizumab + bevacizumab combination therapy divided by prior treatment with molecular-targeted agents (CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.